Subscribe to Newsletter
Business & Profession Health Economics and Policy

An Uncertain Future

Alun Evans

As you may be aware, five of the US Medicare administrative contractors (MACs) are withdrawing their local coverage determinations (LCDs) for a number of microinvasive glaucoma surgery (MIGS) procedures. Though this announcement has been welcomed by companies that would have been negatively impacted by the potential changes to Medicare coverage, the need for the U-turn does not diminish a sense of uncertainty.

Sudden turnarounds are not new. Only a couple of years ago – driven by mounting pressure from the American Academy of Ophthalmology (AAO) and the American Society of Cataract and Refractive Surgery (ASCRS) – Aetna rescinded its policy of requiring preauthorization for cataract surgeries (in every state except Georgia and Florida) after only one year.

It would be remiss, of course, to suggest that all ophthalmologists were against the proposed MIGS coverage changes taking place. Admittedly casting his view from the other side of the Atlantic, Power List alumnus Gus Gazzard, Consultant Ophthalmic Surgeon at Moorfields Eye Hospital, and UCL Professor of Ophthalmology at the Institute of Ophthalmology UCL and the NIHR Biomedical Research Centre, UK, told The Ophthalmologist earlier this year: “While many see this LCD ruling as terrible, I personally see it as a step towards common sense distribution of resources and the limiting of patients to risk of harm only when we know the device works. The designation of treatments as ‘investigational’ until there is randomized controlled trial (RCT) evidence is, in my view, long overdue, and moreover is precisely how we manage things at Moorfields in the UK.”

However, Gazzard did append his statement with a reservation about what the ruling could have meant for ophthalmic development: “I do worry that this will limit innovation – slow it down, but not stifle it – but that may be the price we have to pay for keeping patients safe and using funds wisely.” Whether or not you agree with this view, it’s one that could be reiterated in the months and years to come – both in the US and abroad.

Whatever the future, the unfolding drama of MIGS coverage has cast a shadow on the glaucoma care landscape. Will it influence developers and investors interested in dipping their toes in the MIGS market? Will ophthalmologists-in-training reconsider their career options? Well, with glaucoma cases increasing to an estimated 112 million people by 2040 (1), ophthalmologists who specialize in glaucoma are likely to be in demand like never before – whatever the treatment options available to them.

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. Y Lin et al., “The Global Burden of Glaucoma: Findings from the Global Burden of Disease 2019 Study and Predictions by Bayesian Age–Period–Cohort Analysis,” Journal of Clinical Medicine, 12, 1828 (2023). PMID: 36902615.
About the Author
Alun Evans

Coming from a creative writing background, I have a great interest in fusing original, narrative-driven concepts with informative, educational content. Working at The Ophthalmologist allows me to connect with the great minds working in the field of contemporary eye care, and explore the human element involved in their scientific breakthroughs.

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine



The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: